Company news
Entera Bio Ltd. news in 2024
Entera Bio Ltd.'s news releases, calls and decks from 2024, newest first.
Entera Bio Reports Q3 2024 Financial Results and Provides Business Updates
November 7, 2024
Entera Bio and OPKO Health Provide Update on PK/PD Results of Oral Oxyntomodulin (GLP-1/Glucagon) Peptide Tablet Candidate for Obesity and Metabolic Disorders
September 24, 2024
Entera Bio to Participate in Upcoming Investor and Scientific Conferences
August 19, 2024
Entera Bio Reports Q2 2024 Financial Results and Provides Business Updates
August 8, 2024
Entera’s EB613, the First Once Daily PTH(1-34) Tablet Treatment Dedicated to Post-Menopausal Women with High Risk Osteoporosis Abstract Selected for Presentation at the ASBMR 2024 Annual Meeting - Key SABRE Update Also Expected
July 31, 2024
Entera Bio Reports Phase 1 Clinical Data of First-in-Class, Oral PTH(1-34) Peptide Candidate (EB612) for Patients with Hypoparathyroidism at ENDO 2024
June 2, 2024
Entera Bio Appoints Dr. Rachel B Wagman as Key Clinical Advisor and Scientific Advisory Board Member
May 14, 2024
Entera Bio to Present Phase 1 Data from First-in-Class, PTH(1-34) Peptide Tablets (EB612) for the Treatment of Hypoparathyroidism at ENDO 2024
May 12, 2024
Entera Bio Reports Q1 2024 Financial Results and Provides Business Updates
May 9, 2024
Entera Bio Announces Publication of Oral PTH(1-34) Peptide Tablets (EB613) Phase 2 Trial Data in the Journal of Bone and Mineral Research
April 7, 2024
Entera Bio Announces Key Regulatory Milestone for Oral PTH(1-34) Peptide (EB613) Phase 3 Program: FDA Ruling on Qualifying BMD as a Surrogate Endpoint for Osteoporosis Drugs is Expected Within 10 Months
March 25, 2024
Entera Bio Announces Robust Pharmacokinetic Data for First-in-Class Oral GLP-2 Peptide Tablet Treatment for Patients with Short Bowel Syndrome
March 19, 2024
Entera Bio Announces Full Year 2023 Financial Results and Provides Business Updates
March 7, 2024
Entera Bio Regains Compliance with Nasdaq Minimum Bid Price Requirement
March 3, 2024
Entera Bio to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
January 29, 2024
Entera Bio Receives Extension from Nasdaq to Regain Compliance with Minimum Bid Price Rule
January 2, 2024